Valuation: Alpha Cognition Inc.

Market Cap 269M 192M 168M 158M 144M 18.45B 271M 1.9B 732M 9.38B 722M 706M 30.19B P/E 2026 *
-6.72x
P/E 2027 * -14.3x
Enterprise Value 269M 192M 168M 158M 144M 18.45B 271M 1.9B 732M 9.38B 722M 706M 30.19B EV / Sales 2026 *
7.54x
EV / Sales 2027 * 3.94x
Free-Float
94.67%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 2021-04-11
Chief Tech/Sci/R&D Officer - 2021-03-21
Director of Finance/CFO 48 2024-10-20
Director TitleAgeSince
Director/Board Member 41 2021-03-17
Director/Board Member 66 2021-03-21
Director/Board Member 58 2021-04-11
Change 5-day change 1-year change 3-year change Capi.($)
+12.55%+2.64% - - 192M
+0.04%+3.34%+53.32%+100.52% 1,028B
-0.09%+1.66%+53.24%+66.45% 651B
-0.02%+2.66%+18.65%+71.97% 466B
-1.22%+3.66%+34.59%+38.81% 346B
-0.79%+2.73%+17.73%+25.11% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+45.91% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+98.11% 186B
Average +1.29%+3.26%+25.25%+45.35% 400.19B
Weighted average by Cap. -0.04%+3.09%+34.84%+61.60%

Financials

2026 *2027 *
Net sales 35.71M 25.49M 22.23M 20.99M 19.06M 2.45B 35.86M 251M 97.03M 1.24B 95.76M 93.64M 4B 68.4M 48.83M 42.58M 40.2M 36.51M 4.69B 68.69M 482M 186M 2.38B 183M 179M 7.66B
Net income -40.14M -28.66M -24.99M -23.59M -21.43M -2.75B -40.31M -283M -109M -1.4B -108M -105M -4.5B -19.9M -14.21M -12.39M -11.7M -10.62M -1.36B -19.99M -140M -54.08M -693M -53.37M -52.19M -2.23B
Net Debt - -
Logo Alpha Cognition Inc.
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!